• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

    26.99 +1.42 (+5.55%)
    Streaming Delayed Price Updated: 11:10 AM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Olema Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Participate in Upcoming Investor Conferences
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Participate in Upcoming Investor Conferences
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Participate in Upcoming Investor Conferences
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports First Quarter 2025 Financial and Operating Results
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Participate in Upcoming Investor Conferences
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
    From Olema Oncology
    Via GlobeNewswire
    News headline image
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.